TARGETED THERAPIES Afatinib-new therapy option for EGFR-mutant lung cancer

被引：82

作者：

Yu, Helena A. ^{[1
]}

Pao, William ^{[2
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv,Div Solid Tumor Oncol, New York, NY 10065 USA

[2] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN 37212 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2013年 / 10卷 / 10期

关键词：

1ST-LINE TREATMENT; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; PHASE-3; TRIAL;

D O I：

10.1038/nrclinonc.2013.154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.

引用

页码：551 / 552

页数：2

共 50 条

[11] Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
Bian, Dongliang
Sun, Liangdong
Hu, Junjie
Duan, Liang
Xia, Haoran
Zhu, Xinsheng
Sun, Fenghuan
Zhang, Lele
Yu, Huansha
Xiong, Yicheng
Huang, Zhida
Zhao, Deping
Song, Nan
Yang, Jie
Bao, Xiao
Wu, Wei
Huang, Jie
He, Wenxin
Zhu, Yuming
Jiang, Gening
Zhang, Peng
NATURE COMMUNICATIONS, 2023, 14 (01)
[12] Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations
Liu, Wenliang
Ren, Siying
Xiao, Ying
Yang, Lulu
Zeng, Chao
Hu, Yan
FRONTIERS IN PHARMACOLOGY, 2022, 13
[13] Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
Lee, Jiyun
Piotrowska, Zofia
Soo, Ross
Cho, Byoung Chul
Lim, Sun Min
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[14] Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC
Kulkarni, Amit A.
Fujioka, Naomi
Reinhardt, Lucia
Patel, Manish R.
Kratzke, Robert A.
LUNG CANCER MANAGEMENT, 2022, 11 (01)
[15] Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors
Landi, Lorenza
Tiseo, Marcello
Chiari, Rita
Ricciardi, Serena
Rossi, Elisa
Galetta, Domenico
Novello, Silvia
Milella, Michele
D'Incecco, Armida
Minuti, Gabriele
Tibaldi, Carmelo
Salvini, Jessica
Facchinetti, Francesco
Haspinger, Eva Regina
Cortinovis, Diego
Santo, Antonio
Banna, Giuseppe
Catino, Annamaria
GiajLevra, Matteo
Crino, Lucio
de Marinis, Filippo
Cappuzzo, Federico
CLINICAL LUNG CANCER, 2014, 15 (06) : 411 - 417
[16] Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Kim, Youjin
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
Park, Keunchil
Sun, Jong-Mu
CANCER RESEARCH AND TREATMENT, 2019, 51 (02): : 502 - 509
[17] Afatinib plus Cetuximab First-line in EGFR-Mutant Lung Cancer-Letter
Cortot, Alexis B.
Moro-Sibilot, Denis
Cadranel, Jacques
CLINICAL CANCER RESEARCH, 2016, 22 (07) : 1827 - 1827
[18] Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
Janjigian, Yelena Y.
Smit, Egbert F.
Groen, Harry J. M.
Horn, Leora
Gettinger, Scott
Camidge, D. Ross
Riely, Gregory J.
Wang, Bushi
Fu, Yali
Chand, Vikram K.
Miller, Vincent A.
Pao, William
CANCER DISCOVERY, 2014, 4 (09) : 1036 - 1045
[19] AZD3759 for CNS metastases in EGFR-mutant lung cancer
Planchard, David
LANCET RESPIRATORY MEDICINE, 2017, 5 (11) : 841 - 842
[20] Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer?
Kulkarni, Amit A.
Naqash, Abdul Rafeh
Puri, Sonam
Dienstmann, Rodrigo
JCO PRECISION ONCOLOGY, 2021, 5 : 408 - 414

← 1 2 3 4 5 →